Andere Sprachen Syndax Pharmaceuticals, Inc.

Aktien

A2AFL6

US87164F1057

SNDX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
21.06 ^USD	+2.38%		+1.25%	-2.55%

08.04.	Syndax Pharmaceuticals, Inc. präsentiert positive pädiatrische Daten aus der zulassungsrelevanten AUGMENT-101-Studie mit Revumenib bei rezidivierter/refraktärer akuter KMT2Ar-Leukämie auf der ASPHO-Plenarsitzung	CI
28.03.	Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals gibt den Abschluss der Patientenrekrutierung für die AUGMENT-101-Zulassungsstudie bei Patienten mit rezidivierter/refraktärer akuter myeloischer Leukämie (mNPM1) bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum	10.04.
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	09.04.
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	08.04.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05.04.
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	28.03.
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia	27.03.
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment	26.03.
Syndax Says Revumenib NDA Granted FDA Priority Review	26.03.
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia	26.03.
Sector Update: Health Care Stocks Rise Monday Afternoon	18.03.
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer	18.03.
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer	18.03.
Syndax Pharmaceuticals, Inc. Announces Executive Changes	18.03.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	01.03.
Syndax: Q4 Earnings Snapshot	27.02.
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Syndax Announces Participation at Two Upcoming Investor Conferences	26.02.
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024	20.02.
Certain Restricted Stock Units of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024.	13.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Syndax Pharmaceuticals, Inc.

Aktien

A2AFL6

US87164F1057

SNDX

Andere Sprachen

Filter